RT Journal Article
SR Electronic
T1 Modelling the impact of rapid tests, tracing and distancing in lower-income countries suggest that optimal policies vary with rural-urban settings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253853
DO 10.1101/2021.03.17.21253853
A1 Xilin Jiang
A1 Wenfeng Gong
A1 Zlatina Dobreva
A1 Ya Gao
A1 Matthew Quaife
A1 Christophe Fraser
A1 Chris Holmes
YR 2022
UL http://medrxiv.org/content/early/2022/09/08/2021.03.17.21253853.abstract
AB Low- and middle-income countries (LMICs) remain of high potential for hotspots for COVID-19 deaths and emerging variants given the inequality of vaccine distribution and their vulnerable healthcare systems. We aim to evaluate containment strategies that are sustainable and effective for LMICs. We constructed synthetic populations with varying contact and household structures to capture LMIC demographic characteristics that vary across communities. Using an agent- based model, we explored the optimal containment strategies for rural and urban communities by designing and simulating setting-specific strategies that deploy rapid diagnostic tests, symptom screening, contact tracing and physical distancing. In low-density rural communities, we found implementing either high quality (sensitivity > 50%) antigen rapid diagnostic tests or moderate physical distancing could contain the transmission. In urban communities, we demonstrated that both physical distancing and case finding are essential for containing COVID-19 (average infection rate < 10%). In high density communities that resemble slums and squatter settlements, physical distancing is less effective compared to rural and urban communities. Lastly, we demonstrated contact tracing is essential for effective containment. Our findings suggested that rapid diagnostic tests could be prioritised for control and monitor COVID-19 transmission and highlighted that contact survey data could guide strategy design to save resources for LMICs. An accompanying open source R package is available for simulating COVID-19 transmission based on contact network models.Competing Interest StatementDisclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Bill and Melinda Gates Foundation (BMGF). Financial & competing interests disclosure: Wenfeng Gong is an employee at the Bill and Melinda Gates Foundation. Xilin Jiang and Ya Gao served as consultants to the BMGF. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding StatementComputation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. We thank Microsoft China Co. Ltd. for computation power during the exploration stage of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code generated during this study is bundled up, with an R-package available at: https://github.com/Xilin-Jiang/NetworkCOVID19. Please refer to the GitHub page for installing the package and setting parameters for replicating our results or performing other contact network based analysis. https://github.com/Xilin-Jiang/NetworkCOVID19